AI Article Synopsis
Article Abstract
Background: Tuberculosis is one of the transmitted diseases that has been claimed as one of the most serious health problems worldwide resulting in death, as reported in WHO in Global Tuberculosis Report 2014. It has been predicted that 9 million people suffer from tuberculosis disease and 1.5 - 2 million deaths occur by this disease.
Objective: The aim of this research is to know the species of plant used as anti-hematemesis medicine that has the activity of antituberculosis and antituberculosis-MDR and then investigate the phytochemistry characteristics of the compound from every parts of the plant extract that show the activity of antituberculosis and antituberculosis-MDR which is indicated by the value of Minimum Inhibitory Concentration (MIC) of the extracts.
Methods: The extraction method used in this research was the maceration method. The antituberculosis activity test was investigated using MODS and LJ media methods. The isolation of the active compound was carried out using Bioassay Guided Fractionation and then the compound characteristics were identified using spectroscopy data.
Results: The results showed that extracts from Talas (Collocasia esculenta tuber) and Kariango (Acorus calamus rhizome) plants were active against M. tuberculosis. The FTIR spectroscopy data showed that three isolates obtained from Talas plants contained aliphatic OH and C-O and CH groups. The MIC values of kariango and Talas extracts using the MODS method were 45 mg/ml and 40 mg/ml, respectively.
Conclusion: Talas (Collocasia esculenta) tuber and Kariango rhizome ethanolic extract have a potency for antituberculosis and anti-MDR tuberculosis drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1871526520666191216121302 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting InhA in drug-resistant Mycobacterium tuberculosis: potent antimycobacterial activity of diaryl ether dehydrozingerone derivatives.
Arch Microbiol
January 2025
Clinical Microbiology and PK-PD Division, CSIR-Indian Institute of Integrative Medicine, Sanatnagar, Srinagar, J&K, 190005, India.
Tuberculosis (TB) remains a major global threat, with 10 million new cases and 1.5 million deaths each year. In multidrug-resistant tuberculosis (MDR-TB), resistance is most commonly observed against isoniazid (INH) and rifampicin (RIF), the two frontline drugs.
View Article and Find Full Text PDFTuberculous Subclavian Artery Pseudoaneurysm in a Young Male With Hemoptysis.
Cureus
December 2024
Vascular Surgery, Unidade Local de Saúde São José, Lisbon, PRT.
Subclavian artery pseudoaneurysms (SAPs) are rare and most often secondary to trauma. On the contrary, a mycotic origin is exceedingly rare, and defining this etiology can become challenging. We present a rare case of a tuberculous SAP in a young patient.
View Article and Find Full Text PDFAntimycobacterial activity of luteolin in resistant Mycobacterium tuberculosis isolates and cytotoxicity on L929 cells.
Microb Pathog
January 2025
Department of Medical Microbiology, Inonu University, Malatya, Türkiye. Electronic address:
Mycobacterium tuberculosis (M. tuberculosis) bacteria can cause oxidative stress and the production of inflammatory cytokines, creating an environment that enhances tumour formation, progression and metastasis. Epidemiological studies have found a link between lung cancer and tuberculosis (TB), but the cellular mechanism is still unclear.
View Article and Find Full Text PDFSafety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial.
Lancet Microbe
December 2024
Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, Germany; German Center for Infection Research, Munich Partner Site, Munich, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection, and Pandemic Research, Munich, Germany; Unit Global Health, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. Electronic address:
Background: The broad use of bedaquiline and pretomanid as the mainstay of new regimens to combat tuberculosis is a risk due to increasing bedaquiline resistance. We aimed to assess the safety, bactericidal activity, and pharmacokinetics of BTZ-043, a first-in-class DprE1 inhibitor with strong bactericidal activity in murine models.
Methods: This open-label, dose-expansion, randomised, controlled, phase 1b/2a trial was conducted in two specialised tuberculosis sites in Cape Town, South Africa.
Macrophage Activation Syndrome in a Patient with Systemic Lupus Erythematous Triggered by Tuberculous Meningitis.
Eur J Case Rep Intern Med
December 2024
Internal Medicine, Dubai Health, Dubai, United Arab Emirates.
Background: Hemophagocytic lymphohistiocytosis (HLH), is characterized by systemic uncontrolled inflammation resulting from immune dysregulation secondary to various triggers, including genetics, infections, autoimmune diseases, and malignancies. Macrophage activation syndrome (MAS) is an immune dysregulation phenomenon, in which an underlying rheumatological disease is present. We report a rare, interesting case of a middle-aged female, with a systemic lupus erythematosus (SLE) flare complicated by macrophage activation syndrome (MAS), in which tuberculous meningitis (TBM) was the identified trigger.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!